Hakimian Rina, Korn David
Division of Biomedical and Health Sciences Research, Association of American Medical Colleges, Washington, DC 20037, USA.
JAMA. 2004 Nov 24;292(20):2500-5. doi: 10.1001/jama.292.20.2500.
Academic and industrial scientists have sharply increased their demand for properly prepared and clinically annotated tissue samples that yield valuable insights into the origins and expressions of human disease. Historically, research on human tissue samples has been relatively unencumbered by federal regulations and occurred without delineation of ownership rights to the specimens, patient data, or research products. As regulations have become increasingly restrictive, and because clear ownership interests have never been established, the presumed right of researchers and institutions to collect, use, and dispose of specimens and their associated patient data has remained undefined and occasionally contentious. Recent examination of these issues by a US federal court resulted in a ruling that individuals do not retain rights of ownership or control of biological materials contributed for research, regardless of whether commercial benefit accrues. This article examines the legal, regulatory, and ethical framework within which human tissue research is currently conducted. We contend that because the benefits of medical knowledge derived from tissue research potentially accrue to all individuals and future generations (rather than a single recipient), society may justify an expansive use of these valuable resources for future studies.
学术和产业科学家对经过妥善准备和具有临床注释的组织样本的需求急剧增加,这些样本能为人类疾病的起源和表达提供有价值的见解。从历史上看,对人体组织样本的研究相对较少受到联邦法规的限制,并且在没有明确标本、患者数据或研究产品所有权的情况下进行。随着法规变得越来越严格,而且由于从未确立明确的所有权权益,研究人员和机构收集、使用和处置标本及其相关患者数据的假定权利仍然不明确,偶尔还会引发争议。美国一家联邦法院最近对这些问题进行审查后做出裁决,个人对为研究提供的生物材料不保留所有权或控制权,无论是否产生商业利益。本文探讨了当前进行人体组织研究的法律、监管和伦理框架。我们认为,由于从组织研究中获得的医学知识的益处可能惠及所有个人和后代(而非单个接受者),社会可以为将这些宝贵资源广泛用于未来研究提供正当理由。